Dublin, Nov. 23, 2018 (GLOBE NEWSWIRE) -- The "Connected Drug Injection Devices to 2024" report has been added to ResearchAndMarkets.com's offering.

For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life. Connected drug injection devices - drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs - are gaining interest among industry and managed care participants.

Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.

Connected Drug Injection Devices - What You Will Learn

• What drug injection devices incorporate wireless connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?
• What benefits do connected drug injectors provide to patients in the area of improved adherence? Patient reported outcomes? HCP/patient communication?
• What therapeutic areas are the current focus of connected devices?
• Who are the companies behind the push to connected injection devices? What are their development activities and corporate alliances and affiliations
• What is the importance of pharma-device alliances and design partnerships on connected drug injection device commercialization and market access?
• What does the current market for connected drug injection devices look like? What will it look like in 2024?
• What are the key market drivers for the growth of connected injection devices?

Key Topics Covered:

1. Executive Summary

2. Injectable Drug Development Trends

• The Rapid Rise of Prefilled Injection Devices
• Factors Driving Drug Self-Administration
• Connectivity Technologies
• Competitive Landscape

3. Connected Devices Deep Dive Analysis

• Enable Wearable Injector (Enable Injections)
• OmniPod (Insulet)
• RebiSmart (Merck Serono)
• BETACONNECT (Bayer HealthCare)
• easypod (EMD Serono)
• Axis-D Connect (Haselmeier)
• Flexi-Q eMU (Elcam Medical)
• YpsoMate/SmartPilot (Ypsomed AG)
• Onejet (Biocorp)
• Datapen (Biocorp)
• KiCoPen (Cambridge Consultants)
• Insulin Pens
• InPen (Companion Medical)
• Esysta Pen (Emperra)
• Third Party Devices
• Gocap (Common Sensing)
• EASYLOG (Biocorp)
• Bee (Vigilant)
• Veta EpiPen Smart Case (Aterica)

4. Near-term Markets and Forecasts

• Anaphylaxis
• Autoimmune Disease
• Multiple Sclerosis
• Cardiovascular
• Diabetes
• Hormone Replacement

5. Market Factors

• Regulatory Requirements
• Data Security
• Patient Acceptance

6. Company Profiles

• Aterica
• Bayer HealthCare
• Biocorp
• Cambridge Consultants
• Common Sensing
• Companion Medical
• EMD Serono
• Elcam Medical
• Emperra
• Enable Injections
• Haselmeier
• Insulet
• Merck Serono
• Vigilant
• Ypsomed AG

For more information about this report visit https://www.researchandmarkets.com/research/q9k248/global_connected?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables , Needles and Syringes